antirabies serum (equine)
Animal productexperimental
Clinical trial activity
4 trials · 6 clinical orgs · 0 marketing orgs
Phase 1
0
Phase 2
2
Phase 3
2
Phase 4
0
Earliest trial started Jun 30, 2012 (NCT01622062)
Timeline
2010s
- Jan 1, 2012
Earliest Phase 3 Sponsor(trial)
Indications
Studied for
Mechanism of action
- Lyssavirus rabiesImmunity, passive
Lyssavirus rabies immunity, passive
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- antirabies serum (equine)
- equine rabies immunoglobulin
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT04478084 | Phase 3 | Aug 4, 2020 | Sanofi, Sanofi-Aventis |
| NCT03524417 | N/A | Apr 30, 2018 | Chulalongkorn University |
| NCT03093545 | N/A | Mar 1, 2015 | Biogentech Co.,LTD, Mahidol University, VINS Bioproducts Ltd. |
| NCT01622062 | Phase 3 | Jun 30, 2012 | Sanofi, Sanofi-Aventis |
Showing 4 of 4 trials
Page 1 / 1
Organizations
Research & Development (6)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Sanofi | For profit | 2 | 2 | 1 | 2012 |
| Sanofi-Aventis | For profit | 2 | 0 | 1 | 2012 |
| Biogentech Co.,LTD | For profit | 1 | 0 | 1 | 2015 |
| Chulalongkorn University | Academic/Hospital | 1 | 1 | 1 | 2018 |
| Mahidol University | Academic/Hospital | 1 | 1 | 1 | 2015 |
| VINS Bioproducts Ltd. | For profit | 1 | 0 | 1 | 2015 |
6 organizations
Page 1 / 1